Clairity
Clairity, Inc. is a healthcare technology company founded in 2020 and headquartered in Boston, Massachusetts. The company's mission is to shift the standard of care for cancer from reactive diagnosis to proactive prevention. Clairity develops AI-powered solutions that leverage deep learning and computer vision to analyze existing screening mammograms and predict a woman's future risk of developing breast cancer. Their flagship product, CLAIRITY BREAST, is the first FDA-authorized AI platform of its kind, offering a five-year future risk assessment using only a mammogram. This technology aims to provide clinicians and patients with actionable, personalized insights, enhancing early detection and prevention efforts. Clairity's business model appears to be SaaS, providing its AI platform to healthcare providers. The company has received notable backing from Santé Ventures and ACE Global Equity, and a $1M investment from the Breast Cancer Research Foundation (BCRF).
Clairity
Clairity, Inc. is a healthcare technology company founded in 2020 and headquartered in Boston, Massachusetts. The company's mission is to shift the standard of care for cancer from reactive diagnosis to proactive prevention. Clairity develops AI-powered solutions that leverage deep learning and computer vision to analyze existing screening mammograms and predict a woman's future risk of developing breast cancer. Their flagship product, CLAIRITY BREAST, is the first FDA-authorized AI platform of its kind, offering a five-year future risk assessment using only a mammogram. This technology aims to provide clinicians and patients with actionable, personalized insights, enhancing early detection and prevention efforts. Clairity's business model appears to be SaaS, providing its AI platform to healthcare providers. The company has received notable backing from Santé Ventures and ACE Global Equity, and a $1M investment from the Breast Cancer Research Foundation (BCRF).
TL;DR
Product: CLAIRITY BREAST — FDA-authorized AI platform that predicts 5-year breast cancer risk from a routine screening mammogram (image-only).
Founding & HQ: Founded 2020; headquartered in Boston, Massachusetts.
Founder / Leadership: Founder & CEO: Dr. Constance “Connie” Lehman, MD, PhD.
Funding & Investors: Series A (2022-10-17); total funding reported $6,670,000 USD; backed by Santé Ventures and ACE Global Equity; received $1M from the Breast Cancer Research Foundation (BCRF).
Company Overview
Problem Domain
Breast cancer risk prediction and prevention using routine medical imaging (mammography).
Founded
2020
Industry
Healthcare AI
Funding Track Record
Series A listed on company financial profiles.
Investor Signal
“Backed by Santé Ventures and ACE Global Equity; received a $1M investment from the Breast Cancer Research Foundation (BCRF).”